secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001628280-25-025075
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027
------------------------------------------------------------------------------

- Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.
- ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.
- Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.
- Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.
- Company expects to sign one or more new partnerships, including with a large pharma, in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/0001628280-25-025075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/absc-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-025075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer